颜廷东
个人简历
颜廷东,男,1981年生, 山东 德州人,博士,教授
江苏特聘教授,南通大学特聘教授。

地址:江苏省南通市啬园路9号南通大学啬园校区16号楼706室
邮编:226001
手机:18302165346
邮箱:yantdntu2018@163.com
邮编:226001
2004年于烟台大学获学士学位,2007年于清华大学/北京协和医学院获硕士学位,2010年于厦门大学获博士学位,2011-2020年在新加坡国立大学等科研机构进行博士后研究工作,2020年起在南通大学药学院以独立PI开展研究工作,建立癌症机理与药物干预实验室。
国家自然科学基金评审专家,担任Frontiers in Cell and Developmental Biology, Frontiers in Nutrition,Journal of Ageing Research等国际学术期刊编委。Aging and Disease, Frontiers in Pharmacology等期刊审稿人。近年来以第一作者或通讯作者在Nature Communications,Cell Research,Cancer Research等重要学术期刊发表SCI论文三十余篇。承担和参与多项国家级和江苏省研究课题。
主要研究领域:
主要从事衰老和肿瘤等疾病的生物学机制研究及干预策略开发,研究体系围绕“靶点发现—机制解析—药物筛选”层层递进,重点覆盖以下三大方向:
一、端粒酶调控机制及靶向药物研发
聚焦干细胞和肿瘤中端粒酶的调控网络,解析hTERT表达及活性调控的关键分子机制,并以此为基础开展新型端粒长度检测技术研发及端粒酶靶向小分子药物的筛选,为抗衰老和抗肿瘤治疗提供新靶点。
二、肿瘤与炎症信号通路研究
围绕NF-κB等核心炎症信号通路,解析其在肿瘤发生发展及炎症调控中的作用机制,并以此为基础在天然产物中筛选具有信号通路干预活性的候选化合物,为肿瘤和炎症相关疾病提供新的治疗策略。
三、黄酮类天然化合物功能性研究
系统研究补骨脂素、黄芩苷、川陈皮素、EGCG等黄酮类活性成分的药理机制,围绕抗炎、抗氧化、抗衰老三方面深入解析其分子机制:
•抗炎:通过NF-κB等信号通路抑制炎症因子(如IL-6、IL-8)表达,调控炎症反应
•抗氧化:通过Nrf2/Keap1等通路调节氧化应激水平,保护细胞免受氧化损伤
•抗衰老:通过SIRT家族及端粒酶相关通路调控细胞衰老进程,延缓衰老相关病理变化
已建立天然产物高通量筛选平台和黄酮类化合物资源库,筛选出多种具有抗炎、抗氧化及端粒酶调控活性的候选化合物,为开发新型天然药物和功能健康产品奠定基础。
上述研究综合运用单细胞测序、ChIP-seq、RNA-seq等生信分析手段,结合分子细胞生物学技术、CRISPR-Cas9筛选平台及小鼠疾病模型,为相关疾病提供新的干预和治疗策略。
主要研究成果:
1.端粒酶调控机制研究及抗衰老/抗肿瘤药物研发
端粒酶是逆转录酶,可延长端粒长度;正常细胞分裂时端粒缩短导致衰老凋亡,而约90%肿瘤细胞中端粒酶被激活。研究发现miR-615-3p可通过结合hTERT 3'UTR抑制端粒酶活性,其宿主基因HOXC5则通过破坏hTERT启动子与增强子的相互作用抑制hTERT表达,二者协同调控端粒酶活性,为肿瘤治疗提供新靶点(Nature Communications, 2018)。进一步发现达那唑通过结合NR4A2激活端粒酶活性,为抗衰老治疗提供新靶点;基于此正在设计并筛选活性更强、更稳定、毒性更小的小分子化合物。与天然产物实验室合作,已从近千种天然产物中筛选出6种可激活端粒酶活性的化合物,相关动物实验正在进行,为抗衰老药物专利申请和成果转化奠定基础。
2.肿瘤与炎症关系研究,聚焦NF-κB等信号通路
揭示了肝癌细胞中RXRα形成的tRXR片段通过与RARγ形成异源二聚体影响其胞质定位,胞质RARγ可与PI3K p85α亚基相互作用激活PI3K/AKT-NF-κB通路,促进肝癌细胞增殖(J Biol Chem 2008;Cancer Research 2010),并以此为靶点开展天然产物活性物质筛选。在非小细胞肺癌研究中,构建NF-κB荧光素酶报告系统及稳定表达细胞系,筛选发现补骨脂素(Corylin)可通过抑制p65核转位显著抑制NF-κB活性及下游IL-6/IL-8表达,抑制肿瘤细胞增殖迁移,为NSCLC治疗提供新的候选化合物(Phytomedicine, 2023)。
3.黄酮类化合物抗炎、抗氧化及抗衰老功能性研究
在抗炎机制方面,除前述补骨脂素靶向NF-κB通路的研究外,还证实黄芩苷可通过SIRT3依赖信号通路抑制压力负荷诱导的心肌肥厚,为黄酮类化合物的心脏保护作用提供机制依据(Phytomedicine, 2023)。在抗氧化机制方面,通过代谢组学解析柚皮苷对对乙酰氨基酚诱导肝损伤的保护作用及其代谢通路调控机制(Oxid Med Cell Longev, 2022)。在抗衰老机制方面,围绕SIRT家族及端粒酶相关通路,系统总结了靶向端粒酶的小分子药物在肿瘤和衰老中的研究进展(Chemico-Biological Interactions, 2023),并解析了人端粒及hTERT启动子中G-四链体结构的调控作用,为黄酮类化合物的抗衰老机制研究及候选药物筛选提供理论基础。
主持和参与的科研课题:
江苏特聘教授特别资助项目2020,200万,主持,2020.9-2023.09
国家自然科学基金面上项目(31972889),CMSS1/RBM34/DDX5复合体调控端粒酶新机制的发现及其在非小细胞肺癌(NSCLC)发生发展中的作用机制,58万,主持,2020.1-2023.12
国家自然科学基金面上项目(30070345),肿瘤增殖调控中的RARγ非基因组效应机制,31万,主要参与者,2010.1-2013.12
获得奖项及荣誉:
1. 2021华夏医学科技奖一等奖 ,项目名称:难治性疾病的间充质干细胞干预策略和关键技术的创新与推广应用。
2. 2016 冷泉港亚洲 端粒和端粒酶会议 奖学金。
3. 2010 厦门大学荣誉学生毕业。
一作及通讯论文 (*共同第一,#共同通讯)
Chang JM, Shan YM, Zhou YH, Lu JW, Ding H, Zhou Y, Ji YF, Tao RJ, Zhu WH,Yan TD#, Liu ZG#. Cimigenoside Attenuates Ulcerative Colitis by Inhibiting Oxidative Stress and Inflammation via Sirtuin 3 Enhancement in Mice.Antioxidants (Basel). 2026 Mar 28;15(4):428. (IF=8.2)
Gu W, Li H, Sun L, Shen Z, Wang Y, Hu X, Wu Y, Liu W, Wan CC, Cai Y,Yan T. The RNA-binding protein CMSS1 promotes the progression of non-small cell lung cancer by regulating the telomerase protein subunit hTERT.Life Sci. 2025 Jan 15;361:123321. (IF=6.4)
Yan T, Nisar MF, Hu X, Chang J, Wang Y, Wu Y, Liu Z, Cai Y, Jia J, Xiao Y, Wan C. Pyrroloquinoline Quinone (PQQ): Its impact on human health and potential benefits. Curr Res Food Sci. 2024 Oct 22;9:100889.(IF=7.7)
Deng Z, Xu Y, Cai Y, Lin W, Zhang L, Jiang A, Zhou Y, Zhao R, Zhao H, Liu Z,Yan T. Inhibition of Ribosomal RNA Processing 15 Homolog (RRP15) Suppressed Tumor Growth, Invasion and Epithelial to Mesenchymal Transition (EMT) of Colon Cancer.Int J Mol Sci. 2023;24(4):3528.(IF:5.6)
Lin Z, Liao L, Zhao S, Gu W, Wang G, Shen Z, Chen K, Liu W, Cai Y, Wan C,Yan T.Corylin inhibits the progression of Non-small cell lung cancer cells by regulating NF-κB signaling pathway via targeting p65.Phytomedicine. (2023) 110:154627.(IF:11.3)
Jiang S, Huang C, Zheng G, Yi W, Wu B, Tang J, Liu X, Huang B, Wu D,Yan T#, Li M, Wan C, Cai Y#. EGCG Inhibits Proliferation and Induces Apoptosis Through Downregulation of SIRT1 in Nasopharyngeal Carcinoma Cells.Front Nutr. (2022) 9:851972. (IF:5.5)
Huang C, Jiang S, Gao S, Wang Y, Cai X, Fang J,Yan T#, Craig Wan C#, Cai Y#. Sirtuins: Research advances on the therapeutic role in acute kidney injury.Phytomedicine.(2022)101:154122. (IF:11.3)
Zhu R*,Yan T*, Feng Y*, Liu Y*, Cao H*, Peng G, Yang Y, Xu Z, Liu J, Hou W, Wang X,et al.Mesenchymal stem cell treatment improves outcome of COVID-19 patients via multiple immunomodulatory mechanisms.Cell Res. (2021) 2021(12):1244-1262. (IF:31.1)
Gu J, Chen C, Wang J, Chen T, Yao W,Yan T#, Liu Z#. Withaferin A Exerts Preventive Effect on Liver Fibrosis through Oxidative Stress Inhibition in a Sirtuin 3-Dependent Manner.Oxid Med Cell Longev. (2020), 2020:2452848. (IF:7.31)
Deng Z, Hassan S, Rafiq M, Li H, He Y, Cai Y, Kang X, Liu Z,Yan T#. Pharmacological Activity of Eriodictyol: The Major Natural Polyphenolic Flavanone.Evid Based Complement Alternat Med. (2020), 2020:6681352. (IF:2.650)
Yan TD, Huang J, Nisar MF, Wan C, Huang W. The Beneficial Roles of SIRT1 in Drug-Induced Liver Injury.Oxid Med Cell Longev. (2019), 2019:8506195. (IF:7.31)
Yan TD, Ooi W.F., Qamra A., Cheung A., Ma D.L., Sundaram G.M., Xu C., Xing M., Poon L.F., Wang J., Loh Y.P., Ho J.H.J., Ng J.J.Q., Ramlee M.K., Aswad L., Rozen S.G., Ghosh S., Bard F.A., Sampath P., Tergaokar V., Davies J.O.J., Hughes J.R., Goh, E., Bi X., Fullwood M.J., Tan P. , Li S. HoxC5 and miR-615-3p target newly evolved genomic regions to repress hTERT and inhibit tumorigenesis.Nature Communications. (2018), 8;9(1):100. (IF:18.1)
Liu CC*, Ma DL*,Yan TD*, Fan X, Poon Z, Poon LF, Goh SA, Rozen SG, Ying Khee Hwang W, Tergaonkar V, Tan P, Ghosh S, Virshup DM, Goh EL, Li S. Distinct responses of stem cells to telomere uncapping – a potential strategy to improve the safety of cell therapy.Stem Cells. (2016), 34(10):2471-2484. (Highlighted on the cover of the issue) (IF:4.8)
Yan TD*, Wu H*, Zhang HP*, Lu N, Ye P, Yu FH, Zhou H, Li WG, Cao X, Lin YY, He JY, Gao WW, Zhao Y, Xie L, Chen JB, Zhang XK, Zeng JZ. Oncogenic Potential of Retinoic Acid Receptor-gamma in Hepatocellular Carcinoma.Cancer Research. (2010), 70(6): 2285-95. (IF:22.6)
其他文章
Tham CY, Poon L,Yan T, Koh JYP, Ramlee MK, Teoh VSI, Zhang S, Cai Y, Hong Z, Lee GS, Liu J, Song HW, Hwang WYK, Teh BT, Tan P, Xu L, Koh AS, Osato M, Li S. High-throughput telomere length measurement at nucleotide resolution using the PacBio high fidelity sequencing platform. Nat Commun. (2023) 14(1):281. (IF:17.694)
Cai Y, Yu SS, He Y, Bi XY, Gao S,Yan TD, Zheng GD, Chen TT, Ye JT, Liu PQ. EGCG inhibits pressure overload-induced cardiac hypertrophy via the PSMB5/Nmnat2/SIRT6-dependent signalling pathways.Acta Physiol (Oxf). (2020), 2020 :e13602.
Xu C, Ooi WF, Qamra A, Tan J, Chua BY, Ho SWT, Das K, Adam Isa ZF, Li Z, Yao X,Yan TD, Xing M, Huang KK, Lin JS, Nandi T, Tay ST, Lee MH, Tan ALK, Ong X, Ashktorab H, Smoot D, Li S, Ng SC, Teh BT, Tan P. HNF4α pathway mapping identifies wild-type IDH1 as a targetable metabolic node in gastric cancer.Gut. (2020), 2018-318025.
Xing M, Ooi WF, Tan J, Qamra A, Lee PH, Li Z, Xu C, Padmanabhan N, Lim JQ, Guo YA, Yao X, Amit M, Ng LM, Sheng T, Wang J, Huang KK, Anene-Nzelu CG, Ho SWT, Ray M, Ma L, Fazzi G, Lim KJ, Wijaya GC, Zhang S, Nandi T,Yan T, Chang MM, Das K, Isa ZFA, Li S, Teh BT, Tan P. Genomic and epigenomic EBF1 alterations modulate TERT expression in gastric cancer.J Clin Invest. (2020), 130(6):3005-3020.
Ramlee MK,Yan TD, Cheung AM, Chuah CT, Li S. High-throughput genotyping of CRISPR/Cas9-mediated mutants using fluorescent PCR-capillary gel electrophoresis.Sci Rep. (2015) 26;5:15587.
Akıncılar SC, Low KC, Liu CY,Yan TD, Oji A, Ikawa M, Li S, Tergaonkar V. Quantitative assessment of telomerase components in cancer cell lines.FEBS Lett. (2015), 589(9):974-84.
Liu CC, Gopalakrishnan V, Poon LF,Yan TD, Li S. Cdk1 regulates the temporal recruitment of telomerase and Cdc13-Stn1-Ten1 complex for telomere replication.Mol Cell Biol. (2014), 34(1):57-70.
Ghosh A, Saginc G, Leow SC, Khattar E, Shin EM,Yan TD, Wong M., Zhang Z., Li G., Sung W.-K., Zhou J., Chng W.J., Li S, Liu E., V. Tergaonkar. Telomerase directly regulates NF-κB-dependent transcription.Nature Cell Biology. (2012), 14(12):1270-81.
Lu N, Liu J, Liu J, Zhang C, Jiang F, Wu H, Chen L, Zeng W, Cao X,Yan TD, Wang G, Zhou H, Lin B, Yan X, Zhang XK, Zeng JZ. Antagonist effect of triptolide on AKT activation by truncated retinoid X receptor-alpha.PLoS One. (2012),7(4):e35722.
Wu H, Lin Y, Li W, Sun Z, Gao W, Zhang H, Xie L, Jiang F, Qin B,Yan TD, Chen L, Zhao Y, Cao X, Wu Y, Lin B, Zhou H, Wong AS, Zhang XK, Zeng JZ. Regulation of Nur77 expression by β-catenin and its mitogenic effect in colon cancer cells.FASEB J. (2011), 25(1):192-205.
Zhou H, Liu W, Su Y, Wei Z, Liu J, Kolluri SK, Wu H, Cao Y, Chen J, Wu Y,Yan TD, Cao X, Gao W, Molotkov A, Jiang F, Li WG, Lin B, Zhang HP, Yu J, Luo SP, Zeng JZ, Duester G, Huang PQ, Zhang XK. NSAID sulindac and its analog bind RXRalpha and inhibit RXRalpha-dependent AKT signaling.Cancer Cell. (2010), 15;17(6):560-73.
Han YH, Zhou H, Kim JH,Yan TD, Lee KH, Wu H, Lin F, Lu N, Liu J, Zeng JZ, Zhang XK. A unique cytoplasmic localization of RARgamma and its regulations.J Biol Chem. (2009),284(27):18503-14.
Naling S, Xin H, Qiren Z,Yan TD, Lei W. Cloning and expression of the tumstatin active peptides-T(7) and its derivant-T(7)-NGR.Clin Exp Med. (2009), 9(2):165-71.
Liu J, Zhou W, Li SS, Sun Z, Lin B, Lang YY, He JY, Cao X,Yan TD, Wang L, Lu J, Han YH, Cao Y, Zhang XK, Zeng JZ. Modulation of orphan nuclear receptor Nur77-mediated apoptotic pathway by acetylshikonin and analogs.Cancer Research. (2008), 68(21):8871–8.